Immune-profiling and cell depletion experiments revealed that melanoma cell-derived Activin-A reduces the dependence on suppressive CD4+ T cells to escape immune surveillance, correlating with the diminished secretion of specific chemokines such as CXCL9 and CXCL10. The gene discussed is CD4; the disease is melanoma.